Esmolol before cardioplegia and as cardioplegia adjuvant reduces cardiac troponin release after cardiac surgery. A randomized trial

E Bignami, Marcello Guarnieri, A. Franco, C Gerli, M De Luca, F Monaco, G Landoni, A Zangrillo

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Cardioplegic solutions are the standard in myocardial protection during cardiac surgery, since they interrupt the electro-mechanical activity of the heart and protect it from ischemia during aortic cross-clamping. Nevertheless, myocardial damage has a strong clinical impact. We tested the hypothesis that the short-acting beta-blocker esmolol, given immediately before cardiopulmonary bypass and as a cardioplegia additive, would provide an extra protection to myocardial tissue during cardiopulmonary bypass by virtually reducing myocardial activity and, therefore, oxygen consumption to zero. Materials and methods: This was a single-centre, double-blind, placebo-controlled, parallel-group phase IV trial. Adult patients undergoing elective valvular and non-valvular cardiac surgery with end diastolic diameter >60 mm and ejection fraction
Original languageEnglish
Pages (from-to)313-320
Number of pages8
JournalPerfusion
Volume32
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Dive into the research topics of 'Esmolol before cardioplegia and as cardioplegia adjuvant reduces cardiac troponin release after cardiac surgery. A randomized trial'. Together they form a unique fingerprint.

Cite this